Suppr超能文献

[肾盂及输尿管癌的临床研究]

[Clinical studies on renal pelvic and ureteral carcinoma].

作者信息

Akino H, Ishida H, Ito Y, Tanase K, Isomatsu Y, Muranaka K, Mori H, Kanamaru H, Okada K

机构信息

Department of Urology, Fukui Medical School.

出版信息

Hinyokika Kiyo. 1997 Apr;43(4):257-62.

PMID:9161851
Abstract

We reviewed 40 patients with renal pelvic and/or ureteral transitional cell carcinomas, consisting of 24 males and 16 females with a mean age of 65 years. The histopathological stage of surgically removed specimen was pTa in 6 patients, pT1 in 7, pT2 in 5, pT3 in 11 and pT4 in 6. Three patients with Tis and 2 with T3 did not undergo surgery. Of 35 patients pathologically examined, lymphatic and venous invasions were detected in 22 (63%) and 16 (46%), respectively, and were associated with pathological stage and grade. Overall the 5-year actuarial survival rate was 57.1%. Tumor staging and vascular invasion had a prognostic significance on the treatment outcome, but not metachronous or synchronous bladder cancer, identified in 55% of the patients. Adjuvant chemotherapy appeared to improve the survival of the patients with tumors pT2 or higher, grade 3 or vascular invasion without metastases.

摘要

我们回顾了40例肾盂和/或输尿管移行细胞癌患者,其中男性24例,女性16例,平均年龄65岁。手术切除标本的组织病理学分期为pTa期6例,pT1期7例,pT2期5例,pT3期11例,pT4期6例。3例Tis期和2例T3期患者未接受手术。在35例接受病理检查的患者中,分别有22例(63%)和16例(46%)检测到淋巴和静脉侵犯,且与病理分期和分级相关。总体而言,5年精算生存率为57.1%。肿瘤分期和血管侵犯对治疗结果具有预后意义,但在55%的患者中发现的异时性或同时性膀胱癌则无此意义。辅助化疗似乎可提高pT2期或更高分期、3级或有血管侵犯且无转移的肿瘤患者的生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验